Physician profile
Mark C Cooper
NPI 1225080849
$1,893.17
in general payments reported to CMS, 2019-2025
28 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $295 · 2021: $287 · 2022: $306 · 2023: $203 · 2024: $437 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.92 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.05 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $208.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $197.81 | 2019-2024 | Fasenra, Farxiga, Airsupra |
| Lilly USA, LLC | $197.76 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $170.74 | 2019-2025 | |
| Abbvie INC. | $103.90 | 2021-2024 | Qulipta |
| Glaxosmithkline, LLC. | $70.54 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.28 | 2019-2022 | |
| Sanofi Pasteur INC. | $56.68 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $53.76 | 2022 | |
| Abbott Laboratories | $46.78 | 2023-2024 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $43.78 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $35.26 | 2023 | Ztlido |
| Allergan, INC. | $34.44 | 2019-2020 | |
| Amgen INC. | $31.71 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.64 | 2021-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.14 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.88 | 2021-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $25.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.04 | 2021 | |
| Sumitomo Pharma America, INC. | $21.58 | 2024 | Gemtesa |
| Seqirus USA INC | $18.33 | 2019 | |
| Medtronic, INC. | $17.81 | 2023 | Minimed 780g |
| Vistapharm, INC. | $17.13 | 2021 | |
| Exact Sciences Corporation | $14.44 | 2025 | Cologuard Collection Kit |
| Tonix Medicines, INC. | $14.05 | 2025 | Tonmya |
| Sanofi-Aventis U.S. LLC | $13.60 | 2020 | |
| Daiichi Sankyo INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.